Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study

[1]  R. D'Agostino.  Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. , 2012, The Journal of infectious diseases.

[2]  N. Reinsch,et al.  Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study , 2012, European journal of preventive cardiology.

[3]  K. Sliwa,et al.  Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. , 2012, European heart journal.

[4]  J. Karbach,et al.  Heart-focused anxiety in the general population , 2012, Clinical Research in Cardiology.

[5]  D. Duprez,et al.  Biomarkers and HIV-associated cardiovascular disease , 2010, Current opinion in HIV and AIDS.

[6]  Klaus Mann,et al.  Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. , 2010, Journal of the American College of Cardiology.

[7]  V. Soriano,et al.  Management of metabolic complications and cardiovascular risk in HIV-infected patients. , 2010, AIDS reviews.

[8]  O. Kirk,et al.  Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[9]  Jeffrey N. Martin,et al.  Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals , 2010, AIDS.

[10]  N. Reinsch,et al.  Prevalence of Cardiac Diastolic Dysfunction in HIV-Infected Patients: Results of the HIV-HEART Study , 2010, HIV clinical trials.

[11]  J. Masjuán,et al.  Cerebrovascular Ischemic Events in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy: Incidence and Risk Factors , 2009, Cerebrovascular Diseases.

[12]  B. Mayosi,et al.  Cardiac manifestations of HIV infection: an African perspective , 2009, Nature Clinical Practice Cardiovascular Medicine.

[13]  Chotikorn Khunnawat,et al.  Cardiovascular manifestations in human immunodeficiency virus-infected patients. , 2008, The American journal of cardiology.

[14]  C. Sabin,et al.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. , 2008, Circulation.

[15]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[16]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[17]  D. Katzenstein,et al.  Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk , 2008, PloS one.

[18]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[19]  C. del Rio.  Updated antiretroviral treatment guidelines from DHHS and EACS. , 2008, AIDS clinical care.

[20]  R. Wachter,et al.  Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. , 2007, European journal of medical research.

[21]  H. Sørensen,et al.  Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  N. Petrosillo,et al.  QT interval prolongation and antiretroviral treatment: another point of interest. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[24]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[25]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[26]  Mark R Wallace,et al.  Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras , 2006, Journal of acquired immune deficiency syndromes.

[27]  D. Waters,et al.  What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection , 2005, Circulation.

[28]  R. Erbel,et al.  Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). , 2005, European journal of medical research.

[29]  A. Folpe,et al.  HIV viral protein R causes atrial cardiomyocyte mitosis, mesenchymal tumor, dysrhythmia, and heart failure , 2005, Laboratory Investigation.

[30]  G. L’italien,et al.  Protease inhibitor exposure and increased risk of cardiovascular disease in HIV‐infected patients , 2005, HIV medicine.

[31]  R. Erbel,et al.  Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients - part III: age differences. , 2004, European journal of medical research.

[32]  O. Kirk,et al.  Cardio- and cerebrovascular events in HIV-infected persons , 2004, AIDS.

[33]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[34]  W. K. Henry,et al.  Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  K. Dingemans,et al.  Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. , 2002, The New England journal of medicine.

[36]  A. Samarel,et al.  Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. , 2002, American journal of physiology. Heart and circulatory physiology.

[37]  E. Furfine,et al.  Metabolic complications associated with antiretroviral therapy. , 2001, Antiviral research.

[38]  J. Dieleman,et al.  Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. , 2001, Journal of acquired immune deficiency syndromes.

[39]  Z. Xie,et al.  HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NF-kappaB activation. , 2000, American journal of physiology. Heart and circulatory physiology.

[40]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[41]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[42]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[43]  S. Lipshultz,et al.  Cardiovascular manifestations of HIV infection. , 1996, Comprehensive therapy.